ESSA Pharma Inc. (EPIX) Shares Up -12.5%
ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) shares shot up 12.5% during trading on Friday . The stock traded as high as $0.37 and last traded at $0.28. 191,729 shares changed hands during trading, an increase of 103% from the average session volume of 94,358 shares. The stock had previously closed at $0.32.
Several brokerages recently commented on EPIX. Dawson James restated a “buy” rating on shares of ESSA Pharma in a report on Thursday, August 3rd. Zacks Investment Research cut shares of ESSA Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, October 3rd. Finally, Bloom Burton cut shares of ESSA Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, September 12th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $4.75.
The company has a debt-to-equity ratio of -3.00, a current ratio of 2.32 and a quick ratio of 2.32.
COPYRIGHT VIOLATION NOTICE: “ESSA Pharma Inc. (EPIX) Shares Up -12.5%” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/essa-pharma-inc-epix-shares-up-12-5/1697327.html.
ESSA Pharma Company Profile
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.
Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.